Financials

Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
20.9
Price to sales ratio
5.9
Dividends per share
2.03
Dividend yield %
1.61

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
330
HLN
Haleon plc American Depositary Shares
10.27 USD-0.96%+1.99%+12.49%+10.79%45.97 B USD
332
TEVA
Teva Pharmaceutical Industries Limited American Depositary Shar
39.40 USD-1.99%-4.74%-2.11%+106.23%45.91 B USD
432
TAK
Takeda Pharmaceutical Company Limited American Depositary Share
20.25 USD-0.64%+3.26%+7.31%+42.76%31.54 B USD
574
VTRS
Viatris Inc. - Common Stock
18.00 USD-2.60%-3.43%+2.74%+73.91%20.67 B USD

Frequently asked questions about ZOETIS INC.

What is the ZOETIS INC. stock price today?

The current price of ZOETIS INC. (ZTS) is 80.99. Over the past 24 hours, the stock has changed by -1.22%. Follow the ZTS chart for real-time price dynamics.

What is the stock ticker of ZOETIS INC.?

ZOETIS INC. trades under the ticker ZTS. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is ZOETIS INC. stock going up?

ZTS has changed by +2.71% over the last week, +15.50% over the last month, and -44.65% over the last year. Review the chart to see whether the current move is part of a broader trend.

What is the market capitalization of ZOETIS INC.?

ZOETIS INC. currently has a market capitalization of 33.47 B. Market capitalization reflects the total market value of a company's outstanding shares and is commonly used to compare companies by size.

Does ZOETIS INC. release financial reports?

Yes. You can track ZOETIS INC. financial reports and review yearly or quarterly fundamentals on metatrader.com, including revenue, net income, dividends, and valuation metrics.

What were ZOETIS INC. earnings last quarter?

Last quarter, ZOETIS INC. reported earnings of 1.65 per share. Earnings per share is one of the key metrics investors use to evaluate a company's profitability and financial performance.

What was ZOETIS INC. revenue for the last quarter?

ZOETIS INC. reported quarterly revenue of 2.47 B. Revenue is one of the main indicators used to evaluate the company's business growth and operating scale.

What was ZOETIS INC. net income for the last quarter?

ZOETIS INC. reported net income of 691 M for the last quarter. The previous quarter showed 601 M, which means net income changed by +14.98%.

Does ZOETIS INC. pay dividends?

ZOETIS INC. paid a dividend per share of 0.53. The current dividend yield is 4.3%. Dividend data can help income-focused investors evaluate the stock.

Is ZOETIS INC. a good dividend stock?

ZOETIS INC. currently has a dividend yield of 4.3%. Previously, the dividend yield was 2.59%, compared with 1.61% a year earlier. When evaluating dividend stocks, investors should also consider earnings, cash flow, and the sustainability of future dividend payments.

How many employees does ZOETIS INC. have?

As of the latest available data, ZOETIS INC. has 14.5 K employees. Workforce size can provide additional context about the company's scale and operations.

What is ZOETIS INC. EBITDA?

ZOETIS INC. EBITDA is 1.02 B, and its EBITDA margin is 41.17%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.

How can I buy ZOETIS INC. stock?

You can buy ZOETIS INC. (ZTS) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in ZOETIS INC. stock?

Investing in ZOETIS INC. requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the ZTS chart and related analysis on metatrader.com as part of your research.

Zoetis Inc. Class A Common Stock

Zoetis Inc., headquartered in Parsippany, New Jersey, is the largest producer of medicine and vaccinations for pets and livestock worldwide. The company's products include antiparasitics, vaccines, products that relieve itch, anti-infectives, products that alleviate pain, animal health diagnostics, as well as hormones, cardiopulmonary, topical and oral hygiene therapeutics, central nervous system drugs, diuretics, antiemetic, euthanasia, and hepato-digestive products. The company has operations in over 50 countries. In 2025, 70% of the company's revenue came from products for pets and 29% of the company's revenues came from products for livestock. In 2025, 54% of the company's revenue came from customers in the United States. Of this revenue, 79% came from products for dogs and cats, 13% came from products for cattle, and 4% came from products for horses. In 2025, 46% of the company's revenue came from international customers. Of this revenue, 53% came from products for dogs and cats, 19% came from products for cattle, 9% came from products for swine, 7% came from products for poultry, and 3% came from products for horses.

News